118 related articles for article (PubMed ID: 29664843)
1. Comparison of Nedaplatin- and Cisplatin-Based Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer Patients: A Propensity Score Analysis.
Li P; Zhang R; Nie Z; Long M; Zhang G; Fu Z
Int J Gynecol Cancer; 2018 Jun; 28(5):1029-1037. PubMed ID: 29664843
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
[TBL] [Abstract][Full Text] [Related]
3. Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer.
Zhang Y; Fan S; Shan M; Zou W; Feng Y; Hou T; Liu X; Wang J
Sci Rep; 2023 Jun; 13(1):9352. PubMed ID: 37291330
[TBL] [Abstract][Full Text] [Related]
4. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised phase 3 trial.
Tang LQ; Chen DP; Guo L; Mo HY; Huang Y; Guo SS; Qi B; Tang QN; Wang P; Li XY; Li JB; Liu Q; Gao YH; Xie FY; Liu LT; Li Y; Liu SL; Xie HJ; Liang YJ; Sun XS; Yan JJ; Wu YS; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Lv X; Wang L; Xia WX; Zhao C; Cao KJ; Qian CN; Guo X; Hong MH; Nie ZQ; Chen QY; Mai HQ
Lancet Oncol; 2018 Apr; 19(4):461-473. PubMed ID: 29501366
[TBL] [Abstract][Full Text] [Related]
5. Postoperative concurrent nedaplatin-based chemoradiotherapy improves survival in early-stage cervical cancer patients with adverse risk factors.
Mabuchi S; Morishige K; Isohashi F; Yoshioka Y; Takeda T; Yamamoto T; Yoshino K; Enomoto T; Inoue T; Kimura T
Gynecol Oncol; 2009 Dec; 115(3):482-7. PubMed ID: 19783286
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy after radiotherapy or concurrent chemoradiotherapy for pelvic lymph node-positive patients with locally advanced cervical cancer: a propensity score matching analysis.
Yuan Y; You J; Li X; Wang W
Int J Gynecol Cancer; 2022 Jan; 32(1):21-27. PubMed ID: 32474447
[TBL] [Abstract][Full Text] [Related]
8. Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a cohort treated by radiotherapy alone.
Mabuchi S; Ugaki H; Isohashi F; Yoshioka Y; Temma K; Yada-Hashimoto N; Takeda T; Yamamoto T; Yoshino K; Nakajima R; Kuragaki C; Morishige K; Enomoto T; Inoue T; Kimura T
Gynecol Obstet Invest; 2010; 69(4):224-232. PubMed ID: 20068328
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
10. Concurrent chemoradiotherapy with nedaplatin after radical hysterectomy in patients with stage IB and II cervical cancer.
Kobayashi Y; Ohara T; Wada Y; Okuda Y; Kondo H; Okuma Y; Suzuki N; Gomi H; Kiguchi K; Ishizuka B
J Obstet Gynaecol Res; 2009 Jun; 35(3):490-4. PubMed ID: 19527388
[TBL] [Abstract][Full Text] [Related]
11. Comparison of carboplatin- and cisplatin-based concurrent chemoradiotherapy in locally advanced cervical cancer patients with morbidity risks.
Nam EJ; Lee M; Yim GW; Kim JH; Kim S; Kim SW; Kim JW; Kim YT
Oncologist; 2013; 18(7):843-9. PubMed ID: 23821328
[TBL] [Abstract][Full Text] [Related]
12. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
13. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
Cao Y; Deng L; Lian S; Jiang Y
J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
[TBL] [Abstract][Full Text] [Related]
14. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
15. A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiation in cervical cancer.
Choi CH; Lee YY; Kim MK; Kim TJ; Lee JW; Nam HR; Huh SJ; Lee JH; Bae DS; Kim BG
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1252-7. PubMed ID: 21075554
[TBL] [Abstract][Full Text] [Related]
16. Intraarterial cisplatin/nedaplatin and intravenous 5-fluorouracil with concurrent radiation therapy for patients with high-risk uterine cervical cancer.
Kawase S; Okuda T; Ikeda M; Ishihara S; Itoh Y; Yanagawa S; Ishigaki T
Gynecol Oncol; 2006 Sep; 102(3):493-9. PubMed ID: 16478629
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?
Sebastião AM; da Silva Rocha LS; Gimenez RD; de Barros LA; Fukushima JT; da Silva SC; da Costa Miranda V; de Souza Caires IQ; de Freitas D; Filho EA; Diz Mdel P
Eur J Obstet Gynecol Reprod Biol; 2016 Jun; 201():161-5. PubMed ID: 27137353
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
Song T; Du D; Zhang X; Fang M; Wu S
Dis Esophagus; 2017 Sep; 30(9):1-10. PubMed ID: 28859362
[TBL] [Abstract][Full Text] [Related]
19. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy.
Hu K; Wang W; Liu X; Meng Q; Zhang F
Radiat Oncol; 2018 Dec; 13(1):249. PubMed ID: 30558636
[TBL] [Abstract][Full Text] [Related]
20. Retrospective Analysis of Concurrent Chemoradiation with Triweekly Cisplatin plus 5-Fluorouracil Versus Weekly Cisplatin in Cervical Cancer.
Sonoda K; Yahata H; Ichinoe A; Okugawa K; Kaneki E; Kawano Y; Kenjo H; Ohgami T; Yagi H; Ohga S; Asai K; Nakamura K; Honda H; Kato K
Anticancer Res; 2015 Jun; 35(6):3447-54. PubMed ID: 26026109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
